Table 1.
Baseline characteristics of the patients
| All patients N=25 | VAS <4 N=6 | VAS ≥4 N=19 | |
|---|---|---|---|
| Age | |||
| Median (range) [year] | 78 (58–88) | 76 (64–80) | 78 (58–88) |
| Total ALP [no (%)] | |||
| <220 U/L | 12 (48%) | 6 (100%) | 6 (31.5%) |
| ≥220 U/L | 13 (42%) | 0 | 13 (68.4%) |
| Gleason score | |||
| <8 | 12 (48%) | 2 (33.3%) | 10 (55.5%) |
| ≥8 | 12 (48%) | 4 (66.7%) | 8 (42.1%) |
| Lines of therapy | |||
| 1 | 20 (80%) | 6 (100%) | 14 (73.7%) |
| 2 | 17 (68%) | 5 (83.3%) | 12 (63.1%) |
| 3 | 9 (36%) | 3 (50%) | 6 (31.5%) |
| 4 | 6 (24%) | 2 (33.3%) | 4 (21%) |
| Kind of drugs [no (%)] | |||
| Docetaxel | 17 (68%) | 4 (66.7%) | 13 (68.4%) |
| Novel hormonal therapy | 16 (64%) | 2 (33.3%) | 14 (77.7%) |
| Cabazitaxel | 8 (32%) | 2 (33.3%) | 6 (31.5%) |
| Other | 7 (28%) | 1 (16.7%) | 6 (31.5%) |
| ECOG performance status score [no (%)] | |||
| ≤2 | 22 (88%) | 6 (100%) | 16 (84.3%) |
| >2 | 3 (12%) | 0 | 3 (15.7%) |
| VAS for pain (median) | 5 | 2 | 6 |
| Pain therapy | |||
| No opioid use | 14 (56%) | 6 (100%) | 8 (42.1%) |
| Opioid use | 11 (44%) | 0 | 11 (57.9%) |
| Extent of disease [no (%)] | |||
| <6 metastases | 1 (4%) | 0 | 1 (5.3%) |
| 6–20 metastases | 15 (60%) | 4 (66.7%) | 11 (57.9%) |
| >20 metastases | 8 (32%) | 2 (33.3%) | 6 (31.5%) |
| Superscan | 1 (4%) | 0 | 1 (5.3%) |
| External beam radiation therapy within 12 weeks [no (%)] | |||
| Yes | 4 (16%) | 1 (16.7%) | 3 (15.7%) |
| No | 21 (84%) | 5 (83.3%) | 16 (84.3%) |
| Bone-targeted agents [no (%)] | |||
| Yes | 4 (16%) | 1 (16.7%) | 3 (15.7%) |
| No | 21 (84%) | 5 (83.3%) | 16 (84.3%) |
| Median biochemical values (range) | |||
| Hemoglobin (g/dL) | 12 | 13.3 | 10.6 |
| Albumin (g/L) | 40 | 43 | 39 |
| Lactate dehydrogenase (U/L) | 315 | 290 | 320 |
| PSA (μg/L) | 79.9 (9–4,560) | 30.3 (9–80) | 123 (7.6–4,560) |
| Median injection of radium-223 | 6 | 6 | 5 |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen; VAS, visual analog scale.